CXCR2 and asthma: Danirixin (DNX), also known as GSK1325756, is an oral selective, competitive reversible inhibitor of CXC chemokine receptor 2 (CXCR2) developed as an anti-inflammatory agent for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD) (Busch-Petersen et al., 2017).